Sanofi is betting $1.53 billion on a novel drug from Sino Biopharmaceutical, securing global rights to a first-in-class ...
In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Kraemer discussed how patients inspire his work, his advice for industry veterans and how he unwinds on the fairway.
NoA Health has appointed Louisa Lee as CEO, putting the former Novo Nordisk and Pfizer employee at the head of the creative agency’s push to take its business global. | NoA Health has appointed Louisa ...
One of the most powerful voices in the biopharma industry, Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp criticism of the FDA’s Vinay Prasad, M.D., and his performance as the chief of | ...
Dr. McDreamy has signed onto yet another cancer awareness initiative. | Dr. McDreamy has signed onto yet another cancer awareness initiative. “Grey’s Anatomy” star Patrick Dempsey, who has worked with ...
FDA’s CRLs reveal critical errors in AstraZeneca’s Saphnelo data, efficacy doubts for GSK’s Exdensur
In a scathing rebuke (PDF) to AstraZeneca, the FDA cited “critical data quality issues that affect key analyses, including the primary endpoint” within a dataset for Saphnelo (anifrolumab) for the ...
Acadia Pharmaceuticals isn’t taking its recent rejection from the European Medicines Agency lying down, vowing to seek a re-examination of the decision from the regulator's Committee for Medicinal | ...
With some 12 years as CEO under his belt, Bavarian Nordic’s Paul Chaplin is telegraphing his exit from the Denmark-based vaccine maker. | With some 12 years as CEO under his belt, Bavarian Nordic’s ...
With a vital obesity launch now underway in the U.S., Novo Nordisk is casting its attention eastward as it shores up the prospects of its Wegovy pill in Europe and beyond. | Novo will invest 432 ...
Since the start of the millennium, podcasts have gone from nonexistent to numbering in the millions, and Edison Research ...
Esperion has acquired Corstasis Therapeutics and its nasal spray Enbumyst, which was approved by the FDA six months ago. Esperion paid $75 million upfront and earmarked $180 million for potential ...
The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results